Granulocyte and monocyte adsorptive apheresis (GMA) is a non-pharmacological therapy used in inflammatory conditions such as ulcerative colitis, Crohn’s disease, and psoriasis. Its efficacy hinges on the interaction between circulating leukocytes and cellulose acetate (CA) beads within the Adacolumn device. These beads selectively bind granulocytes and monocytes through opsonization and adhesion via integrins like CD11b/CD18 (Mac-1), initiating a cascade of anti-inflammatory responses. However, clinical implementation typically occurs at room temperature (~25°C), which may not reflect optimal physiological conditions for cellular activation.
To evaluate the influence of temperature on this process, we conducted an in vitro study comparing leukocyte adsorption to CA beads at 5°C, 25°C, 37°C, and 43°C.p300 Antibody Epigenetics Our results demonstrated a clear temperature dependence: the percentage of adsorbed granulocytes and monocytes significantly increased at 37°C compared to lower temperatures. At 43°C, adsorption remained high but was not significantly greater than at 37°C, suggesting a plateau effect. Notably, no significant adsorption occurred at 5°C, indicating that cold temperatures inhibit the biological activity of both blood cells and the CA surface.
Further analysis revealed that IL-1ra release—critical for GMA’s anti-inflammatory action—was markedly enhanced at 37°C, with levels significantly higher than at 25°C or 5°C. This finding aligns with prior reports linking IL-1ra production to adhesion signaling triggered by cell–bead contact. The correlation between IL-1ra concentration and the percentage of adsorbed leukocytes was strong and positive, reinforcing the notion that effective binding directly drives therapeutic molecule release.
Complement activation was also assessed. While C3a generation was consistent across temperatures, C5a production was significantly elevated at 37°C, indicating stronger terminal complement pathway engagement. This suggests that heating enhances the full spectrum of biological reactions initiated by CA bead exposure. In addition, bFGF and C4a were consumed more efficiently at 37°C, likely due to active uptake by adhered leukocytes, further supporting the role of temperature in modulating functional outcomes.
Interestingly, cytotoxicity assays showed no significant cell death across all temperatures, confirming that the observed effects were not due to thermal damage. Moreover, plasma collected after incubation at 37°C suppressed IL-6 production in activated U937 cells more effectively than plasma from 25°C incubations, underscoring the functional superiority of heated treatment.TTF-1 Antibody web
These findings collectively demonstrate that physiological heating (37°C) optimizes the performance of CA beads in GMA by enhancing leukocyte adsorption, promoting the release of anti-inflammatory mediators, and improving the regulatory capacity of treated plasma.PMID:34545429 The data support the hypothesis that suboptimal temperature during current clinical protocols may limit therapeutic potential. Therefore, integrating controlled warming into the GMA procedure could represent a simple yet impactful innovation to improve patient outcomes. Future clinical trials are warranted to validate these in vitro results and assess the real-world benefits of warmed-GMA therapy.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
